Business Wire

CA-TULA-TECHNOLOGY

10.3.2022 10:02:09 CET | Business Wire | Press release

Share
Liebherr and Tula Join Research Activities

At the International Engine Congress in Baden-Baden (Germany), Liebherr-Components AG and U.S.-based Tula Technology presented the results of their joint study on heavy machinery. Together, the companies carried out research on reducing greenhouse gases (GHG) and nitrogen oxides (NOX ) produced by heavy-duty equipment. Based on simulations, Tula’s diesel Dynamic Skip Fire (dDSF™) software allows the reduction of NOX tailpipe emissions by 41% and carbon dioxide (CO2 ) by 9.5%. For this study, Liebherr Machines Bulle SA provided its D966 engine that operates in a variety of applications, like mobile or maritime cranes and wheel loaders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005030/en/

Integration of software into other Liebherr engines possible

The results of the research could influence the development or manufacturing of off-road equipment worldwide in a positive way. Therefore, Liebherr-Components will continue its activities in designing a “proof of concept” hardware for the integration of Tula’s dDSF software into their engine system. The D966, a very compact 13.5L 6-cylinder diesel engine, will also be used in further tests. In the next step, Liebherr will consider the integration of the dDSF software into other engines in its portfolio.

"Liebherr is a forward-thinking company focusing already today on the challenges that customers around the world will face tomorrow,” says Ulrich Weiss, Managing Director for Research and Development of Combustion Engines at Liebherr Machines Bulle SA. “The reduction of greenhouse gases and nitrogen oxide emissions is the goal that we strive to achieve, while continuously improving our engine’s performance.” The results of the joint study indicate that dDSF plays an important role in addressing these challenges, being part of future solutions, which will help in reaching zero emissions.

Efficient engine operation and low level of tailpipe emissions

R. Scott Bailey, the President and Chief Executive Officer of Tula Technology, explains: “At Tula, we are driven by a passion to increase efficiency in engines and motors of all types and also improve the environment. While there are existing regulations to reduce emissions in off-road machinery and vehicles, more stringent standards are expected within the decade. To comply, equipment manufacturers need solutions like our patented dDSF software to operate engines more efficiently and produce dramatically lower levels of tailpipe emissions.”

Tula’s technologies provide cost-effective solutions that are proven to increase engine efficiency. In series production since 2018, Dynamic Skip Fire (DSF®) uses patented algorithms that choose to skip or fire individual cylinders dynamically to meet an engine’s torque demands. This enables near-peak engine efficiency for cleaner burning, as well as more fuel-efficient vehicles. Noise and vibration are proactively mitigated by manipulating the firing pattern and cylinder loading. As a result, DSF has been deployed in more than 1.5 million passenger vehicles to date. The released study adds to the growing list of successful applications of Tula’s technology for diesel dDSF, including passenger cars, commercial vehicles and heavy machinery – with its main goal to reduce GHG and NOX as major contributors to global warming.

About Tula Technology, Inc.

Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technologies and a robust global patent portfolio of more than 380 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .

About Liebherr-Components AG

In this segment, the Liebherr Group specialises in the development, design, and manufacturing of high-performance components in the field of mechanical, hydraulic and electric drive and control technology. Liebherr-Component Technologies AG, based in Bulle (Switzerland), coordinates all activities in the Components product segment. The extensive product range includes combustion engines, injection systems, engine control units, axial piston pumps and motors, hydraulic cylinders, slewing bearings, gearboxes and winches, switchgear, electronic and power electronics components, and software. The high-quality components are used in cranes and earthmoving machinery, in the mining industry, maritime applications, wind turbines, automotive engineering or in aviation and transport technology. Synergy effects in other product segments of the Liebherr Group are used to drive continuous technological development.

About the Liebherr Group

The Liebherr Group is a family-run technology company with a highly diversified product portfolio. The company is one of the largest construction equipment manufacturers in the world. It also provides high-quality and user-oriented products and services in a wide range of other areas. The Liebherr Group includes over 140 companies across all continents. In 2020, it employed around 48,000 staff and achieved combined revenues of over 10.3 billion euros. Liebherr was founded in Kirchdorf an der Iller in Southern Germany in 1949. Since then, the employees have been pursuing the goal of achieving continuous technological innovation, and bringing industry-leading solutions to its customers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye